Announcements Trials
Browse Landscape

Phase

Phase 1 6

Status

Completed 6

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 6Gynecologic 1

Conditions

Neoplasms 6Neoplasm Metastasis 1

Interventions

Surveys and Questionnaires 65pembrolizumab 56Gemcitabine 54Paclitaxel 51Blood Specimen Collection 45Carboplatin 44Bevacizumab 41Docetaxel 38Cisplatin 33Nivolumab 32Fluorouracil 31Capecitabine 28Radiotherapy 25Pemetrexed 25Irinotecan 25Standard of Care 24Interviews as Topic 24Magnetic Resonance Spectroscopy 23Leucovorin 22Erlotinib Hydrochloride 22atezolizumab 21Cetuximab 21Afatinib 21Oxaliplatin 19trametinib 18Exercise 18Ipilimumab 17Sorafenib 16Cyclophosphamide 16olaparib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Neoplasms × nintedanib × Tumor-Agnostic × Clear all
NCT01022853 2018-07-30

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

Boehringer Ingelheim

Phase 1 Completed
30 enrolled 24 charts
Tumor-Agnostic

Neoplasms

NCT00998296 2015-08-19

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

Boehringer Ingelheim

Phase 1 Completed
70 enrolled 25 charts
Tumor-Agnostic

Neoplasms

NCT00715403 2014-12-02

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

Boehringer Ingelheim

Phase 1 Completed
41 enrolled 24 charts
Tumor-Agnostic

Neoplasms

NCT02182128 2014-07-18

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

Boehringer Ingelheim

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

NCT02182206 2014-07-18

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

Boehringer Ingelheim

Phase 1 Completed
50 enrolled
Tumor-Agnostic

Neoplasms

NCT00730821 2009-08-21

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

Boehringer Ingelheim

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡